IRVINE, CA--(Marketwire - November 17, 2009) -
Highlighted Links |
|
The economic forces that initiated major restructuring throughout the global clinical research industry also sparked a strong sense of shared purpose and community, according to a Paragon Biomedical executive.
The collaborative spirit was evident during formal presentations and informal conversations at the recent Partnerships in Clinical Trials conference in Rotterdam, according to Clareece West, Vice President of Global Business Development at Paragon.
Like the rest of the global economy, the clinical research industry has struggled over the past 18 months, according to West.
“But we’ve seen, especially within the last quarter, the beginning of a very subtle turnaround,” she said. “And what makes this positive development even more reassuring is the growing sense that we are all in this together, and that by building genuinely collaborative relationships, we’ll emerge stronger than before,” she said.
West said her perceptions were validated during conversations she and her Paragon colleagues had at the recent conference, which is one of the European clinical research industry’s largest.
“Clients and vendors talked with us about plans for branching out in 2010,” she said. “Much of the expansion will occur in newer emerging regions that will leverage collaborative relationships between Sponsors and CROs.”
West said the collaborative approach has been central to Paragon’s success since the company’s inception.
“For example, Paragon still works with our very first client,” said West. “In fact, 2009 marks our 20-year anniversary with them and one of the main reasons we’ve been together for so long is our shared commitment to each other.”
Paragon Biomedical is a global, full-service, woman-owned clinical research organization (CRO) providing Phase I through IV clinical research services and support to the world’s pharmaceutical, biotechnology, and medical device companies.
Contact:
Jared Byer
Director of Marketing
Paragon Biomediacal
Email Contact